Abstract
Rare diseases are a major cause of morbidity and mortality in high income countries and have major repercussions on individuals and health care systems. This chapter examines the health economy of rare diseases from two different perspectives: firstly, the study of the economic impact of rare diseases (Cost of Illness studies); and, secondly, cost-effectiveness evaluation, which evaluates both the costs and results of the health care technologies applied in rare diseases. From the point of view of economics, health resource allocation is based on the principle of scarcity, as there are not – and never will be- sufficient resources for all worthy objectives. Hence, policy makers should balance costs and health outcomes. Rare diseases may well represent a significant societal burden that should rightly receive appropriate prioritisation of health care resources. As new and seemingly expensive health care technologies are developed for rare diseases, it will become increasingly important to evaluate potential and real impact of these new technologies in both dimensions: social costs and health outcomes.
Similar content being viewed by others
References
Battista RN (1989) Innovation and diffusion of health related technologies: a conceptual framework. Int J Technol Assess Health Care 5:227–48
Brooks R (1996) EuroQol: the current state of play. Health Policy 37:53–72
Drummond M (1991) Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang? Centre for Health Economics. York: University of York.
Drummond MF, Jefferson TO (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313:275–83
Drummond MF, O’Brien B, Sloddarl GL, Torrance GW (1997). Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford
Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J (2007) Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 23(1):36–42
Evans RW (1983) Health care technology and the inevitability of resource allocation and rationing decisions-part I. JAMA 249:2047–53
Gold MR, Siegel JE, Russell LB, Weinstein MC (1996). Cost-effectiveness in health and medicine. Oxford University Press, New York
Knapp M (2003). Hidden costs of mental illness. Br J Psychiatry 183:477–478
López-Bastida J, Perestelo-Pérez L, Montón-Alvarez F, Serrano-Aguilar P (2008) Social economic costs and health-related quality of life in patients with degenerative cerebellar ataxia in Spain. Mov Disord 23(2):212–7
López-Bastida J, Perestelo-Pérez L, Montón-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL (2009). Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Lateral Scler 10(4):237–43
McCabe C, Claxton K, Tsuchiya A (2005). Orphan drugs and the NHS: should we value rarity? BMJ 331(7523):1016–9
Newhouse JP (1992). Medical care costs: how much welfare loss? J Econ Perspect 6:3–21
Posnett J, Jan S (1996). Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 5:13–23
Rice DP (1994) Cost-of-illness studies: fact or fiction? Lancet 344:1519–20
Torrance GW (1986) Measurement of health state utilities for economic appraisal. A review. J Health Econ 5:1–30
Van der Berg B, Brouwer WB, Koopmanschap MA (2004) Economic valuation of informal care. An overview of methods and applications. Euro J Health Econ 5:36–45
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Netherlands
About this chapter
Cite this chapter
López-Bastida, J., Oliva-Moreno, J. (2010). Cost of Illness and Economic Evaluation in Rare Diseases. In: Posada de la Paz, M., Groft, S. (eds) Rare Diseases Epidemiology. Advances in Experimental Medicine and Biology, vol 686. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9485-8_16
Download citation
DOI: https://doi.org/10.1007/978-90-481-9485-8_16
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-9484-1
Online ISBN: 978-90-481-9485-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)